MIR210 (microRNA 210; HGNC:31587, NCBI Gene 406992) at 11p15.5 encodes miR-210 — the "hypoxamir", the most robustly hypoxia-induced microRNA across cell types: HIF-1α-driven transcription through the promoter's hypoxia-response elements, repressing ISCU (the iron-sulfur cluster scaffold), RAD52 and E2F3 so the hypoxic cell throttles respiration and pauses division — and the circulating signature of tissue hypoxia.
Approved Symbol
MIR210 (HGNC:31587)
Chromosomal Locus
11p15.5
Encoded Product
A 22-nt mature microRNA — the hypoxamir
Primary Pathway
HIF-1α → miR-210 → ISCU / RAD52 / E2F3 repression → the hypoxic adaptation program
Clinical / Therapeutic Role
Circulating hypoxia biomarker; breast and clear-cell renal contexts
Gene Structure & Expression
Structure: The single locus whose promoter carries the hypoxia-response elements — the HIF-binding sites wiring the hypoxic induction at the transcriptional level.
Expression: Every hypoxic context: solid-tumor hypoxic cores, ischemic tissue, placenta; the most reproducible miRNA induction in the hypoxia literature.
Molecular Function & Pathways
Mitochondrial arm: ISCU repression down-shifting the respiratory chain — the oxygen-thrifty reset of hypoxic metabolism with the iron-sulfur-cluster enzymes; the recalibrated redox signaling read against the NADPH oxidase and electron-leak contexts.
Genome and division arms: RAD52 (homologous recombination) and E2F3 repression pausing proliferation in hypoxia; the angiogenesis-adjacent targets completing the adaptation file, alongside TP53- and MYC-route crosstalk.
Ischemia and placenta files: Induced in myocardial and limb ischemia, where repression of ephrin-A3 (EFNA3) supports the endothelial angiogenic response (see heart); elevated in preeclamptic placentas, the hypoxic-placenta signature studied in the reproductive system file.
Clinical & Therapeutic Significance
Biomarker: Circulating miR-210 as the hypoxia readout in breast-cancer and renal-cell panels — the clear-cell-renal file (the VHL-loss tumors' constitutive pseudohypoxic program) its deepest dataset; see kidneys.
Therapeutic direction: Anti-miR-210 concepts in tumor-hypoxia programs; the hypoxamir's induction robustness making it the field's reference hypoxia miRNA.